ClinicalTrials.gg
CompletedNCT01819272Updated Mar 15, 2017Results posted

Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks

A Phase 2 interventional study of Met DR and Met XR in Type 2 Diabetes Mellitus, sponsored by Elcelyx Therapeutics, Inc.. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-03-15.

Sponsored by Elcelyx Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
82nd of 287
240 · median 100
Started
2013
with 15 others
Phase 2
23 of 293
3 open now
Registered
174th of 293
by date

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 82nd largest by enrollment of the 287 interventional ones that give a count, is one of 16 that started in 2013, is one of 23 in phase 2, and was the 174th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compared the effect of delayed-release metformin (Met DR) to placebo and extended release metformin (Met XR) on glycemic control (fasting plasma glucose and HbA1c) and body weight, and assessed the safety and tolerability of a range of doses of Met DR when administered in subjects with type 2 diabetes mellitus (T2DM).

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female with T2DM who was ≥18 and ≤65 years of age at Visit 1
  2. Had a (BMI) of 25.0 kg/m² to 45.0 kg/m², inclusive, at Visit 1
  3. Screening 7.0 to 9.5% (inclusive) at Visit 1 if treated with diet and exercise alone, or 6.0 to 9.5% (inclusive) if on a stable dose of either metformin or DPP-4 inhibitor monotherapy for a minimum of 2 months at Visit 1, or a combination of these 2 agents only on a stable regimen for a minimum of 2 months at Visit 1
  4. Had serum creatinine concentration of \<1.5 mg/dL (male) or \<1.4 mg/dL (female) and an estimated (eGFR) of ≥60 mL/min/1.73 m² based on the Modification of Diet in Renal Disease (MDRD) equation
  5. Had a fasting glucose concentration of \<280 mg/dL at Visit 1
  6. Had a stable body weight, i.e., not varying by >5% for at least 6 months prior to Visit 1 as documented by the investigator
  7. Was male, or if female and met all of the following criteria:

    1. Not breastfeeding
    2. Negative pregnancy test result (human chorionic gonadotropin, beta subunit [βhCG]) at Visit 1 (not applicable to hysterectomized females)
    3. If of child bearing potential (including perimenopausal women who have had a menstrual period within 1 year), must have practiced and be willing to continue to practice appropriate during the entire duration of the study
  8. Had a physical examination and with no abnormalities as judged by the investigator at Visit 1
  9. Had no clinically significant laboratory test values (clinical chemistry, hematology, urinalysis) other than those expected in subjects with diabetes as judged by the investigator at Visit 1
  10. Either was not treated with or had been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to Visit 1:

    1. Hormone replacement therapy (female subjects)
    2. Oral contraceptives (female subjects)
    3. Antihypertensive agents
    4. Lipid-lowering agents
    5. Thyroid replacement therapy
    6. Antidepressant agents
    7. Testosterone therapy (male subjects)
  11. If on chronic thyroid pharmacologic therapy, had a serum thyroid-stimulating hormone test result within the normal range at Visit 1
  12. Was willing and able to follow study procedures
  13. Was able to read, understand, and sign the Form and an Authorization to Use and Disclose Protected Health Information form, answer the study questions, communicate with the investigator, and understand and comply with protocol requirements

Exclusion criteria

Exclusion Criteria:

  1. Had a medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:

    1. Hepatic disease
    2. Renal disease
    3. Gastrointestinal disease
    4. Endocrine disorder except T2DM
    5. Cardiovascular disease
    6. Central nervous system diseases
    7. Psychiatric or neurological disorders
    8. Organ transplantation
    9. Chronic or acute infection (e.g., tuberculosis, , virus, or virus)
    10. Orthostatic hypotension, fainting spells or blackouts
    11. Allergy or
  2. Clinically significant malignant disease (with the exception of basal and squamous cell carcinoma of the skin) within 5 years of Visit 1
  3. Had known hypersensitivity, intolerability, or allergies to metformin HCl or any component of study treatment
  4. Had a physical, psychological, or historical finding that, in the investigator's opinion, would make the subject unsuitable for the study
  5. Current drugs or alcohol abuse or had a history of abuse that in the investigator's opinion would cause the individual to be noncompliant with study procedures
  6. Had major surgery or a blood transfusion within 2 months of Visit 1 or was planning to donate blood during the study, or had a significant blood loss within 2 months prior to Visit 1
  7. Had been treated, was being treated, or was expected to require or undergo treatment with any of the following excluded medications:

    1. Insulin or sulphonylurea treatment within 3 months of Visit 1
    2. GLP-1 receptor agonists and/or thiazolidinedione treatment within 6 months of Visit 1
    3. Nifedipine within 3 months of Visit 1
    4. Systemic by oral, intravenous, intra-articular, or intra-muscular route within 30 days of screening or for more than 1 week within 3 months of Visit 1
    5. Prescription weight loss medications within 3 months of Visit 1
    6. Chronic or frequent use, in the judgment of the investigator, of any drug treatment that affects gastric pH (prescription or over-the-counter), including proton pump inhibitors or any antacids or medications such as Rolaids or Pepcid within 1 month of Visit 1
    7. Had received or planned to receive any iodinated contrast dye within 1 week prior to Visit 1 (Screening)
  8. Had a surgical gastrointestinal procedure that may impact the gut hormonal response to study medication
  9. History or presence of inflammatory bowel disease or other severe gastrointestinal disease, particularly those which may impact gastric emptying, such as gastroparesis, pyloric stenosis, gastric bypass surgery or gastric banding surgery
  10. Had received any drug within 30 days (or five half-lives of the investigational drug, whichever was greater) of Visit 1
  11. Was an immediate family member (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the clinical study site, or was directly affiliated with the study at the clinical study site
  12. Was employed by Elcelyx Therapeutics, Inc. (that is an employee, temporary contract worker, or designee responsible for the conduct of the study)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    600 mg DR

    600 mg delayed-release metformin once daily in the morning

    Drug: Met DR

  • Experimental
    800 mg DR

    800 mg delayed-release metformin once daily in the morning

    Drug: Met DR

  • Experimental
    1000 mg DR

    1000 mg delayed-release metformin once daily in the morning

    Drug: Met DR

  • Active comparator
    1000 mg XR

    1000 mg extended-release metformin once daily in the evening

    Drug: Met XR

  • Active comparator
    2000 mg XR

    2000 mg extended-release metformin once daily in the evening

    Drug: Met XR

  • Placebo comparator
    Placebo

    Placebo once daily in the morning

    Drug: Placebo

Interventions

  • DrugMet DR

    metformin delayed-release tablets

  • DrugMet XR

    metformin extended-release tablets

  • DrugPlacebo

    placebo delayed-release tablets

06

What researchers measure

Primary outcomes

  1. Change in Fasting Plasma Glucose (mg/dL) at 4 Weeks

    Time frame: Baseline and 4 weeks after the first dose of study medication

Secondary outcomes

  1. AUC4-12wk of Change in Fasting Plasma Glucose (mg/dL*Week) Concentrations From Baseline to 12 Weeks

    Time frame: Baseline and 4 to 12 weeks after the first dose of study medication

  2. Change in HbA1c (%) at 12 Weeks

    Time frame: Baseline and 12 weeks after the first dose of study medication

07

Results

Posted Sep 21, 2015

Participant flow

Participant flow — Overall Study
MilestonePlacebo600 mg DR800 mg DR1000 mg DR1000 mg XR2000 mg XR
Started413940404040
Completed353637353633
Not completed633547
Withdrew: Adverse event100200
Withdrew: Lost to follow-up301003
Withdrew: Protocol violation000123
Withdrew: Physician decision010000
Withdrew: Withdrawal of consent012101
Withdrew: Loss of glucose control210120

Outcome measures

PrimaryChange in Fasting Plasma Glucose (mg/dL) at 4 Weeks
Time frame:
Baseline and 4 weeks after the first dose of study medication
Reported as:
Median · mg/dL
Change in Fasting Plasma Glucose (mg/dL) at 4 Weeks
mg/dLPlacebo600 mg DR800 mg DR1000 mg DR1000 mg XR2000 mg XR
Change in Fasting Plasma Glucose (mg/dL) at 4 Weeks-4 (-69 to 48)-11 (-124 to 150)-13 (-62 to 145)-18 (-90 to 113)-12 (-111 to 58)-25 (-110 to 20)
Statistical analysis
  • Placebo vs 600 mg DR · Kruskal-Wallis · p = 0.0670 (p-value for pair-wise comparison without adjustment) · Hodges-lehmann estimation: -9.0 · 95% CI -21.0 to 1.0
  • Placebo vs 800 mg DR · Kruskal-Wallis · p = 0.0057 (p-value for pair-wise comparison without adjustment) · Hodges-lehmann estimation: -14.0 · 95% CI -22.0 to -4.0
  • Placebo vs 1000 mg DR · Kruskal-Wallis · p = 0.1095 (p-value for pair-wise comparison without adjustment) · Hodges-lehmann estimation: -12.0 · 95% CI -25.0 to 3.0
  • Placebo vs 1000 mg XR · Kruskal-Wallis · p = 0.0097 (p-value for pair-wise comparison without adjustment) · Hodges-lehmann estimation: -12.0 · 95% CI -23.0 to -3.0
  • Placebo vs 2000 mg XR · Kruskal-Wallis · p = <0.0001 (p-value for pair-wise comparison without adjustment) · Hodges-lehmann estimation: -28.0 · 95% CI -42.0 to -17.0
SecondaryAUC4-12wk of Change in Fasting Plasma Glucose (mg/dL*Week) Concentrations From Baseline to 12 Weeks
Time frame:
Baseline and 4 to 12 weeks after the first dose of study medication
Reported as:
Median · mg/dL*week
AUC4-12wk of Change in Fasting Plasma Glucose (mg/dL*Week) Concentrations From Baseline to 12 Weeks
mg/dL*weekPlacebo600 mg DR800 mg DR1000 mg DR1000 mg XR2000 mg XR
AUC4-12wk of Change in Fasting Plasma Glucose (mg/dL*Week) Concentrations From Baseline to 12 Weeks4.00 (-784.0 to 698.0)-96.00 (-894.0 to 414.0)-108.00 (-556.0 to 612.0)-156.00 (-782.0 to 522.0)-98.00 (-880.0 to 314.0)-215.00 (-856.0 to 186.0)
Statistical analysis
  • Placebo vs 600 mg DR · Kruskal-Wallis · p = 0.0226 (p-value for pair-wise comparison without adjustment) · Hodges-lehmann estimation: -106.0 · 95% CI -208.0 to -16.00
  • Placebo vs 800 mg DR · Kruskal-Wallis · p = 0.0068 (p-value for pair-wise comparison without adjustment) · Hodges-lehmann estimation: -106.0 · 95% CI -180.0 to -32.00
  • Placebo vs 1000 mg DR · Kruskal-Wallis · p = 0.0071 (p-value for pair-wise comparison without adjustment) · Hodges-lehmann estimation: -152.0 · 95% CI -252.0 to -42.00
  • Placebo vs 1000 mg XR · Kruskal-Wallis · p = 0.0405 (p-value for pair-wise comparison without adjustment) · Hodges-lehmann estimation: -101.0 · 95% CI -208.0 to -4.00
  • Placebo vs 2000 mg XR · Kruskal-Wallis · p = <.0001 (p-value for pair-wise comparison without adjustment) · Hodges-lehmann estimation: -224.0 · 95% CI -334.0 to -118.0
SecondaryChange in HbA1c (%) at 12 Weeks
Time frame:
Baseline and 12 weeks after the first dose of study medication
Reported as:
Least squares mean · HbA1c (%)
Change in HbA1c (%) at 12 Weeks
HbA1c (%)Placebo600 mg DR800 mg DR1000 mg DR1000 mg XR2000 mg XR
Change in HbA1c (%) at 12 Weeks0.45 ± 0.137-0.03 ± 0.1250.00 ± 0.1210.10 ± 0.1240.00 ± 0.132-0.21 ± 0.133
Statistical analysis
  • Placebo vs 600 mg DR · ANCOVA · p = 0.0100 · Ls mean: -0.48 · 95% CI -0.85 to -0.12Factor for treatment and baseline HbA1c as a covariate
  • Placebo vs 800 mg DR · ANCOVA · p = 0.0153 · Ls mean: -0.45 · 95% CI -0.81 to -0.09Factor for treatment and baseline HbA1c as a covariate
  • Placebo vs 1000 mg DR · ANCOVA · p = 0.0611 · Ls mean: -0.35 · 95% CI -0.71 to 0.02Factor for treatment and baseline HbA1c as a covariate
  • Placebo vs 1000 mg XR · ANCOVA · p = 0.0188 · Ls mean: -0.45 · 95% CI -0.83 to -0.08Factor for treatment and baseline HbA1c as acovariate
  • Placebo vs 2000 mg XR · ANCOVA · p = 0.0006 · Ls mean: -0.67 · 95% CI -1.04 to -0.29Factor for treatment and baseline HbA1c as a covariate

Adverse events

Collected over Approximately 83 to 107 days depending on the number of intervening days between study visits. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/41 (0%)9/41 (22%)
600 mg DR—1/39 (2.6%)9/39 (23.1%)
800 mg DR—0/40 (0%)11/40 (27.5%)
1000 mg DR—2/40 (5%)9/40 (22.5%)
1000 mg XR—1/40 (2.5%)8/40 (20%)
2000 mg XR—0/40 (0%)8/40 (20%)
Most frequent serious events
Most frequent serious events
EventPlacebo600 mg DR800 mg DR1000 mg DR1000 mg XR2000 mg XR
Hyperglycaemic hyperosmolar nonketotic syndromeMetabolism and nutrition disorders0/411/390/400/400/400/40
Kidney infectionInfections and infestations0/410/390/401/400/400/40
Intravascular haemolysisBlood and lymphatic system disorders0/410/390/401/400/400/40
LeukocytosisBlood and lymphatic system disorders0/410/390/401/400/400/40
Non-cardiac chest painGeneral disorders0/410/390/400/401/400/40
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlacebo600 mg DR800 mg DR1000 mg DR1000 mg XR2000 mg XR
DiarrhoeaGastrointestinal disorders1/413/391/405/402/402/40
DizzinessNervous system disorders2/410/392/401/402/403/40
Upper Respiratory Tract InfectionInfections and infestations0/412/392/400/401/401/40
HyperglycaemiaMetabolism and nutrition disorders2/412/391/401/401/400/40
NauseaGastrointestinal disorders0/410/391/400/402/401/40
ConstipationGastrointestinal disorders0/411/392/400/400/400/40
Abdominal DistensionGastrointestinal disorders0/410/390/400/402/400/40
SinusitisInfections and infestations0/411/390/402/401/401/40
BronchitisInfections and infestations0/410/390/402/402/400/40
NasopharyngitisInfections and infestations2/410/392/400/400/400/40

Baseline characteristics

ITT Population

Age, Continuous
Age, Continuous(years)Placebo600 mg DR800 mg DR1000 mg DR1000 mg XR2000 mg XRTotal
Mean51.4 ± 10.2253.5 ± 8.3452.6 ± 9.6951.8 ± 9.0551.0 ± 9.6252.0 ± 9.5352.0 ± 9.37
Sex: Female, Male
Sex: Female, Male(Participants)Placebo600 mg DR800 mg DR1000 mg DR1000 mg XR2000 mg XRTotal
Female222127142221127
Male191813261819113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo600 mg DR800 mg DR1000 mg DR1000 mg XR2000 mg XRTotal
Hispanic or Latino17141014101075
Not Hispanic or Latino242530263030165
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo600 mg DR800 mg DR1000 mg DR1000 mg XR2000 mg XRTotal
American Indian or Alaska Native1000001
Asian1030206
Native Hawaiian or Other Pacific Islander0010001
Black or African American119139141268
White283023302427162
More than one race0000000
Unknown or Not Reported0001012
BMI
BMI(kg/m²)Placebo600 mg DR800 mg DR1000 mg DR1000 mg XR2000 mg XRTotal
Mean33.6 ± 5.2833.1 ± 5.7433.5 ± 5.8633.3 ± 5.5532.8 ± 5.2733.7 ± 5.2233.3 ± 5.44
Previous T2DM Regimen
Previous T2DM Regimen(participants)Placebo600 mg DR800 mg DR1000 mg DR1000 mg XR2000 mg XRTotal
Diet and exercise alone37246527
DPP-4 inhibitor alone0100001
Metformin alone352935363033198
Metformin/DPP-4 inhibitor combination32304214
Screening Fasting Plasma Glucose
Screening Fasting Plasma Glucose(mg/dL)Placebo600 mg DR800 mg DR1000 mg DR1000 mg XR2000 mg XRTotal
Mean146.5 ± 36.70147.5 ± 42.56142.4 ± 34.60141.4 ± 29.79139.0 ± 34.22148.9 ± 41.36144.3 ± 36.57
Screening HbA1c
Screening HbA1c(%)Placebo600 mg DR800 mg DR1000 mg DR1000 mg XR2000 mg XRTotal
Mean7.19 ± 0.8387.27 ± 0.8647.17 ± 0.8297.13 ± 0.8997.10 ± 0.8197.17 ± 0.8697.17 ± 0.846

2 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Buse JB, DeFronzo RA, Rosenstock J, Kim T, Burns C, Skare S, Baron A, Fineman M. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care. 2016 Feb;39(2):198-205. doi: 10.2337/dc15-0488. Epub 2015 Aug 18. PubMed 26285584 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2013
First posted
Mar 27, 2013
Start
Apr 2013
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Results first posted
Sep 21, 2015
Last update
Mar 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01819272
Lead sponsor
Elcelyx Therapeutics, Inc.
Responsible party
Sponsor
First posted
Mar 27, 2013
Start date
Apr 2013
Primary completion
Sep 2013
Completion
Sep 2013
Results posted
Sep 21, 2015
Last update
Mar 15, 2017

Study contacts

Andrew Lewin
principal investigator · National Research Institute - Wilshire
Rubin Saavedra
principal investigator · Alliance Against Diabetes / AAD Clinical Research
Lydie Hazan
principal investigator · Axis Clinical Trials
Robert Lipetz
principal investigator · Encompass Clinical Research
Audrey Lacour
principal investigator · Juno Research, LLC - Houston
Donald Hurley
principal investigator · Medical Research South, LLC
Eli M Roth
principal investigator · Sterling Research Group, Ltd. - Auburn
Robert Strzinek
principal investigator · Protenium Clinical Research, LLC
Richard Marple
principal investigator · Castlerock Clinical Research Consultants, LLC
Farah Sultan
principal investigator · Achieve Clinical Research, LLC
Thomas Moretto
principal investigator · American Health Network - Indianapolis
Azazuddin A Ahmed
principal investigator · Apex Medical Research - Illinois
Cynthia Strout
principal investigator · Coastal Carolina Research Center
John Pullman
principal investigator · Big Sky Clinical Research
Gregory Collins
principal investigator · Charlotte Clinical Research
David Hassman
principal investigator · Comprehensive Clinical Research
Leonard Zemel
principal investigator · Creekside Endocrine Associates
Diane Smith
principal investigator · CSRA Partners in Health, Inc.
Julio Rosenstock
principal investigator · Dallas Diabetes and Endocrine Center
David Johnson
principal investigator · Searcy Medical Center
Stephen Ong
principal investigator · MD Medical Research
Cynthia Huffman
principal investigator · Meridien Research - Tampa
Ramon Vargas
principal investigator · New Orleans Center for Clinical Research
Almena Free
principal investigator · Pinnacle Research Group
Douglas Short
principal investigator · PMG Research of Raleigh, LLC
Jonathan Wilson
principal investigator · PMG Research of Winston-Salem, LLC
Alexander White
principal investigator · Progressive Medical Research
Ronald Brazg
principal investigator · Rainier Clinical Research Center
Matthew Davis
principal investigator · Rochester Clinical Research
Charles Fogarty
principal investigator · Spartanburg Medical Research
Ralph DeFronzo
principal investigator · The University of Texas Health Science Center at San Antonio
Craig S Thompson
principal investigator · Craig S Thompson MD LLC
Subodh Bhuchar
principal investigator · Pioneer Research Solutions Inc.
Susan Greco
principal investigator · Jacksonville Center For Clinical Research
Harold Bays
principal investigator · Louisville Metabolic and Atherosclerosis Research Center
Barry Lubin
principal investigator · National Clinical Research - Norfolk, Inc.
Mark Christiansen
principal investigator · Diablo Clinical Research, Inc.
Andrea Lawless
principal investigator · Biofortis, Inc.
Kathryn J Lucas
principal investigator · Diabetes and Endocrinology Consultants, P.C.
Hugo Toro
principal investigator · Juno Research, LLC - Katy
Eva M Heurich
principal investigator · Compass Research, LLC
Chander Arora
principal investigator · RAS Health Ltd
Patricia Buchanan
principal investigator · Willamette Valley Clinical Studies
Thomas Blevins
principal investigator · Texas Diabetes & Endocrinology, P.A. - Austin
Anna Chang
principal investigator · John Muir Physician Network Clinical Research Center
John Hoekstra
principal investigator · National Clinical Research - Richmond, Inc.
Lyle Myers
principal investigator · Kentucky Diabetes Endocrinology Center
Stephanie Shaw
principal investigator · Texas Diabetes and Endocrinology, P.A. - Round Rock
Purvi Mehra
principal investigator · eStudySite
Traci Turner
principal investigator · Metabolic and Atherosclerosis Research Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion